Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

664 - CLASS-05 Trial: A randomized controlled phase III trial of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy vesus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Surgical Oncology;  Radiation Oncology;  Gastric Cancer

Presenters

Hao Liu

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

H. Liu1, G. Li1, J. Yu2, X. Su3, Y. Sun4, J. Hu5, L. Huang6, Z. Zhou7, Y. Li8, J. Yu9, H. Wei10, J. Peng11, Z. Wu12, H. Chen13, S. Cui14, Y. Hu2

Author affiliations

  • 1 General Surgery, nanfang hospital, 510515 - Guangzhou/CN
  • 2 General Surgery, Nanfang Hospital, Southern Medical University, 510515 - Guangzhou/CN
  • 3 Minimally Invasive Gastrointestinal Surgery, Peking University Cancer Hospital, 100142 - Beijing/CN
  • 4 General Surgery, Zhongshan Hospital, Fudan University, Shanghai/CN
  • 5 General Surgery, West China Hospital, Sichuan University, Chengdu/CN
  • 6 Gastrointestinal Surgery, Fujian Provincial Hospital, Fuzhou/CN
  • 7 Gastrointestinal Surgery, Sun Yat-sen University Cancer Center, Guangzhou/CN
  • 8 General Surgery, Guangdong General Hospital, Guangzhou/CN
  • 9 General Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou/CN
  • 10 General Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN
  • 11 Colorectal And Annal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN
  • 12 General Surgery, Meizhou People's Hospital, Meizhou/CN
  • 13 General Surgery, Zhongshan City People Hospital, Zhongshan/CN
  • 14 Abdominal Surgery, Cancer Center of Guangzhou Medical University, Guangzhou/CN
More

Resources

Abstract 664

Background

Peritoneal metastasis (PM) is detected synchronously in ∼30% of patients with advanced gastric cancer (AGC), which has been considered as late stage of the disease with a poor prognosis and were generally treated with systemic chemotherapy or best supportive care. Two new surgical modalities that have evolved to manage PM are cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Our and other published retrospective data suggested that CRS plus HIPEC may prolong overall survival of the patients with limited PM. Still, the solid evidences based on large randomized clinical trials (RCT) are lacking. Accordingly, the present trial was initiated to define a comprehensive treatment.

Trial design

The investigator-initiated, multicenter, prospective two-arm RCT is comparing efficacy of CRS followed by HIPEC (CRS+HIPEC) versus chemotherapy (5-Fu based regimen, Chemo) alone for the treatment of AGC with limited PM. Eligibility for the trial is given in cT3-4NxM1 (M1 limited to peritoneum, PCI score < 20 evaluated by diagnostic laparoscopy)AGC. The trial will recruit 220 participants who are 1:1 randomized to one of two arms after diagnostic laparoscopy. Participants enrolled in the Chemo study arm will receive standard chemotherapy according to the NCCN guideline. The CRS+HIPEC study arm will receive D2 gastrectomy plus peritonectomy plus HIPEC followed by systemic chemotherapy. The primary endpoint of the trial is overall survival. The secondary endpoints include progression-free survival, morbidity and mortality and quality of life. Biological substudies on biomarkers are included. Current status: The trial was approved by the Ethical Committee of Nanfang hospital, Southern Medical University, Guangzhou, China. Patient recruitment has begun in January 2017. Overall 12 Chinese sites will commence recruitment in 2017.

Clinical trial identification

NCT03023436

Legal entity responsible for the study

Nanfang Hospital, Southern Medical University

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.